Resmetirom

PHILADELPHIA — In this video, Nancy S. Reau, MD, FAASLD, AGAF, provides an overview of her postgraduate course presentation at the ACG Annual Scientific Meeting.

PHILADELPHIA — In this video, Paul Kwo, MD, professor of medicine and director of hepatology at Stanford University, discusses data from the ongoing MAESTRO-NASH trial, which were presented at the ACG Annual Scientific Meeting.

With the FDA label for Rezdiffra excluding the need for liver biopsy, experts proposed recommendations to “fill the gap” on how to leverage noninvasive tests to assess treatment response in metabolic dysfunction-associated steatohepatitis.

Patients with metabolic dysfunction-associated steatohepatitis who weigh more than 100 kg or a BMI more than 35 kg/m² had “slightly better” response with a 100 mg dose of Rezdiffra, according to data presented at EASL Congress.

Both 80 mg and 100 mg doses of resmetirom achieved liver biopsy endpoints at 52 weeks in patients with nonalcoholic steatohepatitis and had a safety profile consistent with previous reports, according to primary MAESTRO-NASH trial results.

Topline findings from the phase 3 MAESTRO-NASH trial showed that resmetirom at both 100 mg and 80 mg doses improved resolution of nonalcoholic steatohepatitis without worsening fibrosis, Madrigal Pharmaceuticals announced.

A recent study showed that outpatient antibiotic management was safe compared with in-hospital care for patients with acute appendicitis.

LONDON — Resmetirom was safe and well tolerated at 100 mg and 80 mg doses in patients with nonalcoholic steatohepatitis, according to late-breaking research presented at the International Liver Congress.

In patients with heterozygous familial hypercholesterolemia already taking maximally tolerated lipid-lowering medication, resmetirom lowered LDL, triglycerides, apolipoprotein B and lipoprotein(a) levels vs. placebo, researchers reported.

Providers should closely monitor people with diabetes and other high-risk adults for nonalcoholic fatty liver disease and consider multiple noninvasive tests to detect the presence of advanced fibrosis, according to a speaker.